サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513843

結核治療の世界市場

Tuberculosis Therapeutics

出版日
ページ情報
英文 283 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.69円
結核治療の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 283 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結核治療の世界市場は2030年までに11億米ドルに達する見込み

2023年に8億8,620万米ドルと推定される結核治療の世界市場は、分析期間2023～2030年にCAGR 2.7%で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである活動性結核治療は、CAGR 2.9％を記録し、分析期間終了時には6億5,430万米ドルに達すると予測されます。潜在性結核治療セグメントの成長率は、分析期間中CAGR 2.4％と推定されます。

米国市場は2億4,050万米ドルと推定、中国はCAGR4.7%で成長予測

米国の結核治療市場は、2023年に2億4,050万米ドルと推定されます。世界第2位の経済大国である中国は、2023～2030年にかけてCAGR 4.7%で推移し、2030年には予測市場規模2億860万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と2.4％と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

結核治療-主要動向と促進要因

結核は依然として世界的に最も根強く、致命的な感染症のひとつであり、毎年数百万人の命を奪っています。結核菌は主に肺に感染するが、他の臓器に播種することもあります。結核は治癒可能かつ予防可能な病気であるにもかかわらず、特に中低所得国において、公衆衛生上の重大な課題をもたらし続けています。結核の治療には通常、イソニアジド、リファンピシン、ピラジナミド、エタンブトールなど複数の抗生物質を6ヵ月にわたって長期投与します。多剤耐性結核（MDR-TB）や広範囲薬剤耐性結核（XDR-TB）の出現は、治療レジメンをさらに複雑にしており、新しい治療や治療戦略の開発が必要となっています。最近の進歩により、ベダキリンやデラマニドのような新規薬剤が導入され、耐性株に対する有効性が示され、この回復力の強い病原体との闘いに新たな希望がもたらされています。

結核治療の状況は、薬剤開発と診断技術の両面で大きな進歩を遂げ、進化しています。患者のコンプライアンスと治療成績を向上させるため、結核治療期間の短縮に重点を置く研究者が増えています。合剤の採用より治療が簡素化され、患者の錠剤負担が軽減され、アドヒアランスが向上しました。さらに、現在利用可能なBCGワクチンよりも優れた予防効果を発揮するワクチンの開発にも力を入れています。診断法も、Xpert MTB/RIFアッセイのような迅速分子試験法の登場により改善され、結核やリファンピシン耐性を数時間以内に検出できるようになり、タイムリーで適切な治療開始が可能になりました。さらに、患者中心のアプローチやデジタルヘルスによる介入が結核治療に組み込まれ、治療のアドヒアランスを監視し、サポートを提供することで、治療を成功させるための社会的・行動的障壁のいくつかに対処しています。

結核治療市場の成長は、いくつかの要因によってもたらされます。分子生物学とゲノミクスの進歩により、新しい薬剤標的の同定が容易になり、より効果的で毒性の低い結核治療の開発につながりました。政府や国際機関からの資金援助が増加し、研究開発活動に拍車がかかっています。薬剤耐性結核菌の増加により、新たな治療が急務となっており、市場の需要を牽引しています。さらに、世界保健機関（WHO）の結核撲滅戦略（End TB Strategy）など、結核撲滅を目指す公衆衛生上の取り組みが、新たな治療の開発への注力を強めています。ナノ技術を駆使した製剤などドラッグデリバリー・システムの技術革新により、薬剤のバイオアベイラビリティと患者の転帰が改善されています。また、高負担地域の人々の意識の高まりと積極的な医療受診行動も、市場拡大に寄与しています。最後に、治療のアドヒアランスを高めるためのデジタルヘルス技術の統合と、疾病動向を監視するための強固なサーベイランスシステムの導入は、市場の成長を促す極めて重要な要因です。

調査対象企業の例（注目の37社）

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブ概要

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6337

Global Tuberculosis Therapeutics Market to Reach US$1.1 Billion by 2030

The global market for Tuberculosis Therapeutics estimated at US$886.2 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2023-2030. Active TB Therapeutics, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end of the analysis period. Growth in the Latent TB Therapeutics segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$240.5 Million While China is Forecast to Grow at 4.7% CAGR

The Tuberculosis Therapeutics market in the U.S. is estimated at US$240.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$208.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Tuberculosis Therapeutics - Key Trends and Drivers

Tuberculosis (TB) remains one of the most persistent and deadly infectious diseases globally, claiming millions of lives each year. The bacterium Mycobacterium tuberculosis primarily affects the lungs but can disseminate to other organs. Despite being a curable and preventable disease, TB continues to pose significant public health challenges, particularly in low- and middle-income countries. The treatment of tuberculosis typically involves a prolonged course of multiple antibiotics, including isoniazid, rifampicin, pyrazinamide, and ethambutol, over a period of six months. The emergence of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has further complicated treatment regimens, necessitating the development of new therapeutics and treatment strategies. Recent advancements have introduced novel drugs like bedaquiline and delamanid, which have shown efficacy against resistant strains, providing new hope in the fight against this resilient pathogen.

The landscape of TB therapeutics is evolving with significant advancements in both drug development and diagnostic technologies. Researchers are increasingly focusing on shortening the duration of TB treatment to improve patient compliance and outcomes. The introduction of fixed-dose combination drugs has simplified therapy, reducing the pill burden on patients and enhancing adherence. Moreover, efforts are being made to develop vaccines that can provide better protection than the currently available Bacille Calmette-Guérin (BCG) vaccine. Diagnostics have also seen improvements with the advent of rapid molecular tests such as the Xpert MTB/RIF assay, which can detect TB and rifampicin resistance within hours, enabling timely and appropriate treatment initiation. Furthermore, patient-centered approaches and digital health interventions are being integrated into TB care to monitor treatment adherence and provide support, thereby addressing some of the social and behavioral barriers to successful treatment.

The growth in the tuberculosis therapeutics market is driven by several factors. Advances in molecular biology and genomics have facilitated the identification of new drug targets, leading to the development of more effective and less toxic TB drugs. Increased funding from governments and international organizations has spurred research and development activities. The rising prevalence of drug-resistant TB strains has created an urgent need for new treatments, thereby driving market demand. Additionally, public health initiatives aimed at TB elimination, such as the World Health Organization's End TB Strategy, have bolstered the focus on developing new therapeutics. Technological innovations in drug delivery systems, such as nanotechnology-based formulations, have improved drug bioavailability and patient outcomes. The growing awareness and proactive healthcare-seeking behavior among populations in high-burden regions are also contributing to market expansion. Lastly, the integration of digital health technologies to enhance treatment adherence and the implementation of robust surveillance systems to monitor disease trends are pivotal factors fueling market growth.

Select Competitors (Total 37 Featured) -

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Tuberculosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Drug-Resistant TB Strains Drives Demand for New Treatments
    • Public Health Initiatives Strengthen Business Case for Novel Therapeutics
    • Increased Funding and Government Initiatives Expand Addressable Market Opportunity
    • Advances in Molecular Biology and Genomics Propel Growth
    • Technological Innovations in Drug Delivery Systems Accelerate Demand for Advanced Therapies
    • Growing Awareness and Proactive Healthcare-Seeking Behavior Spur Market Growth
    • Improved Diagnostic Technologies Propel Growth in Early Detection and Treatment
    • Development of Shorter Treatment Regimens Generates Demand for New Drug Combinations
    • Vaccine Development and Research Throws the Spotlight on Preventive Measures
    • Implementation of Robust Surveillance Systems Drives Demand for Data-Driven Solutions
    • Nanotechnology-Based Formulations Expand Addressable Market Opportunity
    • Economic Burden of TB Creates Opportunities for Cost-Effective Therapeutics
    • Focus on TB Eradication Worldwide Generates Demand for Comprehensive Solutions
    • Social and Behavioral Interventions Enhance Patient Engagement and Drive Adoption
    • Personalized Medicine and Tailored Therapies Sustain Growth by Improving Efficacy and Outcomes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tuberculosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Active TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Latent TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for First-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Second-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • JAPAN
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • CHINA
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • EUROPE
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • FRANCE
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • GERMANY
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • INDIA
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Tuberculosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Tuberculosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030
  • AFRICA
    • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2014, 2024 & 2030

IV. COMPETITION